Skip to main content

Table 1 Demographic, clinical and laboratory data from the 65 included patients

From: Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up

Data All patients
Age (SD) 50.5 (13.4)
Female (%) 56 (86.1)
Afro-Brazilians (%) 25 (38.4)
Disease duration years (SD) 10.6 (7.7)
Telangiectasia (%) 29 (44.6)
Dyspnea 22 (33%)
Urate levels (SD) 4.5 (1.4)
Left axix deviation 2
FVC % (SD) 77.8 (16.9)
DLco % (SD) 64 (24.1)
FVC/Dlco (SD) 1.3 (0.6)
Detected TRJ (%) 49 (75)
mPAP echocardiography mmHg (SD) 31.9 (14.8)
ANA nucleolar (%) 26 (40)
Antibody positive (%) 27 (41.5)
Anti-Scl-70 (%) 12 (18.4)
Anti-centromere (%) 12 (18.4)
  1. FVC forced vital capacity, Dlco diffusion capacity for monoxide carbon, TRJ tricuspid regurgitation velocity, mPAP mean pulmonary arterial pressure, ANA antinuclear antibody, anti-Scl-70: anti-scleroderma-70 antibody